| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $863,947 | 1 | 0 |
Sells | $1,481,183,551 | 338 | 100 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 1 | $863,947 | 226 | $995.58M | $-994.71M |
| MALCOLM JAN | director | 0 | $0 | 8 | $347,950 | $-347,950 |
| Mesa Nilda | director | 0 | $0 | 3 | $355,542 | $-355,542 |
| Olian Judy D. | director | 0 | $0 | 4 | $416,998 | $-416,998 |
| CAUSEY CHRISTOPHER | director | 0 | $0 | 5 | $2.33M | $-2.33M |
| KURZWEIL RAY | director | 0 | $0 | 1 | $2.4M | $-2.4M |
| Thompson Tommy G | director | 0 | $0 | 3 | $2.51M | $-2.51M |
| PATUSKY CHRISTOPHER | director | 0 | $0 | 3 | $2.73M | $-2.73M |
| SULLIVAN LOUIS W | director | 0 | $0 | 1 | $3.05M | $-3.05M |
| MAHON PAUL A | EVP & GENERAL COUNSEL | 0 | $0 | 25 | $110.54M | $-110.54M |
| BENKOWITZ MICHAEL | PRESIDENT AND COO | 0 | $0 | 23 | $145.01M | $-145.01M |
| EDGEMOND JAMES | CFO AND TREASURER | 0 | $0 | 38 | $227.32M | $-227.32M |
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue …
Over the last 12 months, insiders at United Therapeutics Corporation have bought $863,947 and sold $1.48B worth of United Therapeutics Corporation stock.
On average, over the past 5 years, insiders at United Therapeutics Corporation have bought $863,947 and sold $485.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ROTHBLATT MARTINE A (Chairperson & CEO) — $863,947.
The last purchase of 1,500 shares for transaction amount of $863,947 was made by ROTHBLATT MARTINE A (Chairperson & CEO) on 2026‑05‑26.
| 2026-11-02 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0223% | $596.22 | $5.66M | +0.85% | |
| 2026-10-30 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0224% | $600.09 | $5.7M | +0.00% | |
| 2026-10-29 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 2,720 0.0064% | $592.49 | $1.61M | ||
| 2026-10-29 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0222% | $594.78 | $5.65M | +0.87% | |
| 2026-10-28 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0221% | $585.49 | $5.56M | +1.87% | |
| 2026-10-27 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.022% | $587.73 | $5.58M | +0.83% | |
| 2026-10-26 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0221% | $588.64 | $5.59M | +0.34% | |
| 2026-10-23 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0221% | $582.76 | $5.54M | +1.03% | |
| 2026-10-22 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0221% | $583.38 | $5.54M | +1.44% | |
| 2026-10-21 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.022% | $560.07 | $5.32M | +5.21% | |
| 2026-10-20 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0221% | $553.87 | $5.26M | +6.89% | |
| 2026-10-19 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0222% | $543.32 | $5.16M | +8.85% | |
| 2026-10-16 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0222% | $534.66 | $5.08M | +10.55% | |
| 2026-10-15 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0224% | $546.65 | $5.19M | +8.49% | |
| 2026-10-15 | Sale | MAHON PAUL A | EVP & GENERAL COUNSEL | 8,300 0.0195% | $544.30 | $4.52M | +8.49% | |
| 2026-10-14 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0224% | $539.99 | $5.13M | +8.70% | |
| 2026-10-13 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0225% | $545.52 | $5.18M | +7.93% | |
| 2026-10-12 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0223% | $550.70 | $5.23M | +6.46% | |
| 2026-10-09 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0221% | $544.94 | $5.18M | +6.49% | |
| 2026-10-08 | Sale | ROTHBLATT MARTINE A | Chairperson & CEO | 9,500 0.0224% | $534.31 | $5.08M | +7.76% |
| ROTHBLATT MARTINE A | Chairperson & CEO | 324443 0.7564% | $195.09M | 31 | 1366 | +20.16% |
| PATUSKY CHRISTOPHER | director | 1490 0.0035% | $895,966.80 | 5 | 73 | <0.0001% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 484 | +64.62% | 6M | +14.05% |
| Decreased Positions | 323 | -43.12% | 5M | -12.79% |
| New Positions | 199 | New | 1M | New |
| Sold Out Positions | 57 | Sold Out | 1M | Sold Out |
| Total Postitions | 910 | +21.5% | 42M | +1.27% |
| Blackrock, Inc. | $2.66M | 12.45% | 5.35M | +19,288 | +0.36% | 2025-09-30 |
| Vanguard Group Inc | $2.19M | 10.28% | 4.42M | -30,238 | -0.68% | 2025-09-30 |
| Renaissance Technologies Llc | $1.08M | 5.05% | 2.17M | +54,300 | +2.56% | 2025-09-30 |
| Avoro Capital Advisors Llc | $1M | 4.7% | 2.02M | -347,778 | -14.67% | 2025-09-30 |
| State Street Corp | $954,998.00 | 4.47% | 1.92M | -244,902 | -11.3% | 2025-09-30 |
| Wellington Management Group Llp | $694,802.00 | 3.25% | 1.4M | -44,155 | -3.06% | 2025-09-30 |
| Geode Capital Management, Llc | $620,731.00 | 2.91% | 1.25M | +49,295 | +4.11% | 2025-09-30 |
| Aqr Capital Management Llc | $490,003.00 | 2.29% | 986,478 | -286,683 | -22.52% | 2025-09-30 |
| Darwin Global Management, Ltd. | $371,820.00 | 1.74% | 748,550 | +748,550 | New | 2025-09-30 |
| Lsv Asset Management | $341,103.00 | 1.6% | 686,710 | -177,913 | -20.58% | 2025-09-30 |